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hronic obstructive pulmonary 
disease (COPD) is a major 
and increasing global health 
epidemic that has received insufﬁ  cient 
attention from the health-care 
profession, governments, and the 
pharmaceutical industry. Urgent 
action is now required to recognise 
the disease, predicted to soon become 
one of the major causes of death and 
disability, and to develop more effective 
prevention and treatment strategies.
What Is COPD?
COPD is described by the Global 
Initiative for Chronic Obstructive Lung 
Disease as “a preventable and treatable 
disease…characterized by airﬂ  ow 
limitation that is not fully reversible. 
The airﬂ  ow limitation is usually 
progressive and associated with an 
abnormal inﬂ  ammatory response of the 
lung to noxious particles or gases” [1]. 
This progressive and relentless loss of 
lung function is caused by emphysema 
due to destruction of lung parenchyma 
and by narrowing of small airways as 
a result of chronic inﬂ  ammation and 
ﬁ  brosis and loss of elastic recoil. This 
results in progressive airﬂ  ow limitation, 
air trapping, and progressive shortness 
of breath on exertion.
The Size of the Problem
The Global Burden of Disease studies 
ranked COPD as the sixth commonest 
cause of death worldwide in 1990, 
and it was predicted to become the 
third commonest cause by 2020 [2]. 
A more recent projection from the 
World Health Organization predicts 
that it will rise from its current ranking 
as ﬁ  fth commonest cause of death to 
be the fourth commonest by 2030, 
behind only ischemic heart disease, 
cerebrovascular disease, and HIV/AIDS 
[3]. The increase is predicted to be 
greater in developing countries than 
afﬂ  uent countries. Indeed, COPD is 
the only common cause of death in 
the United States that has increased 
over the last 40 years, in sharp contrast 
to the reduction in cardiovascular 
and infectious diseases. Even more 
importantly, COPD is an increasing 
cause of chronic disability and is 
predicted to become the ﬁ  fth most 
common cause of chronic disability 
worldwide by 2020 [2]. The prevalence 
of COPD is approximately 10% in the 
general population throughout the 
world [4,5]. Many patients with COPD 
remain undiagnosed even when the 
disease causes severe disability [6]. 
Consultation rates for COPD 
in general practice in the United 
Kingdom now exceed those of ischemic 
heart disease by 2-4-fold, and COPD 
is one of the commonest causes of 
hospital admission in the UK [7]. 
COPD is also one of the commonest 
reasons for time lost from work, placing 
an enormous and increasing economic 
burden on society. This has resulted in 
major health-care expenditure that now 
exceeds the costs of asthma by over 
3-fold [6]. The reasons for the global 
increase in COPD include continuing 
cigarette smoking amongst men, with 
increasing smoking amongst women, 
and the longer survival of populations; 
these changes are particularly relevant 
in developing countries.
The Neglect of COPD
Despite growing recognition as 
an important international health 
problem, COPD has suffered neglect 
from clinicians, researchers, and the 
pharmaceutical industry [8]. This 
is largely because COPD is viewed 
as self-inﬂ  icted (by smoking) and 
also because the underlying disease 
process is generally perceived to be 
irreversible. Consequently, there is a 
fundamental lack of knowledge about 
the cellular, molecular, and genetic 
causes of COPD. Existing therapies 
for COPD are inadequate and none 
have been shown to slow the relentless 
progression of the disease. In terms 
of research funding, COPD has been 
relatively neglected among common 
diseases, with little investment in 
research into its underlying cellular 
and molecular mechanisms. COPD is 
now recognised to have the greatest 
socioeconomic inequality of any 
common disease and is commonly a 
disease of the poor, suggesting that 
there are environmental factors other 
than smoking contributing to the 
disease. Indeed, over 10% of patients 
with a clinical diagnosis of COPD are 
non-smokers, and this proportion 
is much higher amongst women in 
developing countries such as India, 
where exposure to biomass fuels in an 
enclosed space is an important cause of 
COPD [9].
Natural History
The classical epidemiological studies 
of Fletcher and Peto demonstrated 
that death and disability from COPD 
were related to an accelerated decline 
in lung function with time, with a loss 
of 50–100 ml in forced expiratory 
volume in one second (FEV1) per 
year, compared to the normal loss 
of <30 ml per year. Only about 10% 
of smokers were thought to develop 
COPD, suggesting that genetic or 
other environmental factors may play 
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an important role in susceptibility. 
Apart from FEV1, exercise capacity, 
exacerbation frequency, and systemic 
features all indicate a poor prognosis 
[10]. A more recent epidemiological 
study with a longer follow-up (25 years) 
suggests that over 25% of smokers may 
develop COPD, with no difference in 
susceptibility between men and women 
[11]. The implication of this study is 
that the prevalence of COPD amongst 
smokers is likely to rise even more as 
people survive longer.
Inadequate Current Therapy
Smoking cessation strategies have 
a poor success rate, with the most 
effective approaches yielding a quit 
rate of only about 15% [12]. In any 
case, stopping smoking as the disease 
becomes more severe has little impact 
on its progression [13], and several 
studies have now shown that smoking 
cessation fails to reverse the chronic 
airway inﬂ  ammation [14]. This stresses 
the need for more effective anti-
smoking strategies, including new 
and more effective drugs for nicotine 
addiction, and earlier intervention. 
Anti-inﬂ  ammatory drugs, which 
are used so successfully to manage 
asthma, have few clear beneﬁ  cial 
effects in COPD and there is a very 
poor response to corticosteroids due 
to an active resistance against the 
anti-inﬂ  ammatory actions of steroids 
[15]. Bronchodilators, which are the 
mainstay of current drug therapy, do 
not signiﬁ  cantly affect the underlying 
disease process and therefore do 
not slow disease progression towards 
respiratory failure and death. New 
treatments for COPD, including the 
development of new classes of drugs, 
are urgently needed [16], and although 
progress has recently been made in 
understanding the molecular, cellular, 
and genetic mechanisms involved in 
COPD, far more research is required in 
this area [17]. This may lead to a better 
understanding of the mechanisms 
for disease progression and to the 
development of effective therapies in 
the future.
What Are the Solutions?
It is clearly necessary to increase 
awareness of COPD amongst health-
care professionals, the general public, 
and governments. General practitioners 
must be educated about how to 
recognize COPD and institute the 
most appropriate therapy. The Global 
Initiative for Chronic Obstructive Lung 
Disease plays an important role in 
raising awareness of COPD amongst 
health-care professionals and has 
formulated updated evidence-based 
guidelines for diagnosis, therapy, and 
prevention [1]. Stopping smoking 
early is very important, particularly 
for those in the early stages of the 
disease, in whom smoking cessation has 
a clear beneﬁ  t and reduces mortality 
[18]. More research is needed into 
the underlying disease mechanisms, to 
identify the genetics of susceptibility 
and to identify new targets for 
treatment. It is increasingly recognised 
that there is heterogeneity in the 
disease and more careful phenotyping 
is required in the future to elucidate 
disease mechanisms and optimise 
novel therapies. This will require much 
more investment from funding bodies 
and governments. The attitude that 
smoking-related lung diseases are self-
induced and therefore less worthy of 
attention needs to be changed; this 
attitude does not appear to apply to the 
same extent to ischemic heart disease, 
diabetes, or obesity. Non-smoking 
causes of COPD will require far more 
attention in the future and the genetic 
and environmental cofactors that 
interact with COPD need to be more 
carefully explored. Far more research 
needs to be done in developing 
countries where non-smoking causes 
of COPD account for a much greater 
proportion of COPD than in developed 
countries. The striking socioeconomic 
disparities in COPD prevalence 
implicate factors other than smoking, 
but these factors have so far largely 
been ignored. In the UK, respiratory 
disease, which includes COPD, receives 
less funding in relation to the burden 
of disease than any other disease 
area [19]. COPD will undoubtedly 
place an increasing burden on health 
resources and this burden is likely to 
be particularly severe in developing 
countries. Finally, COPD needs to be 
more prominently featured in peer-
reviewed journals that address global 
health issues—as recently pointed out 
by the editors of this journal [20].  
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